Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, February 2007

Altmetric Badge

Mentioned by

patent: 14 patents

Citations

dimensions_citation: 100 Dimensions

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 14 patents that reference this research output.

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

Mentioned by

Citations

Readers on

Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Grant US-11464774-B2

United States of America

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Grant US-11110086-B2

United States of America

Substituted pyrazines as ATR kinase inhibitors

Grant US-10961232-B2

United States of America

Processes for preparing ATR inhibitors

Grant US-10822331-B2

United States of America

Treating cancer with ATR inhibitors

Grant US-10813929-B2

United States of America

Substituted pyrazin-2-amines as inhibitors of ATR kinase

Grant US-10479784-B2

United States of America

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Grant US-10478430-B2

United States of America

Processes for preparing ATR inhibitors

Grant US-10208027-B2

United States of America

Processes for making compounds useful as inhibitors of ATR kinase

Grant US-9862709-B2

United States of America

Method for measuring ATR inhibition mediated increases in DNA damage

Grant US-9791456-B2

United States of America

Substituted pyrazines as ATR kinase inhibitors

Grant US-9701674-B2

United States of America

Compounds useful as inhibitors of ATR kinase

Grant US-9630956-B2

United States of America

Substituted pyrazin-2-amines as inhibitors of ATR kinase

Grant US-9365557-B2

United States of America

Compounds useful as inhibitors of ATR kinase

Grant US-9334244-B2

United States of America